Back | Next |
home / stock / lexx / lexx message board
Subject | By | Source | When |
---|---|---|---|
what does this mean? | all4weed | investorshub | 05/12/2023 3:03:00 AM |
$LEXX Price trading | willlbone | investorshub | 05/11/2023 10:03:19 PM |
https://www.accesswire.com/754344/Lexaria-Bioscience-Announces-Closing-of-20-Mil | Shawking | investorshub | 05/11/2023 6:02:30 PM |
A swing and a miss | hdhick | investorshub | 05/11/2023 5:03:31 PM |
As we look towards 2022 and 2023, Lexaria | Shawking | investorshub | 05/11/2023 4:01:43 PM |
The gaining up | PotsandPans420 | investorshub | 05/11/2023 12:07:17 PM |
Cheap target for a hostile takeover Bunka needs | codfather | investorshub | 05/10/2023 5:50:24 PM |
Thoughts on where this is headed? | Shawking | investorshub | 05/10/2023 1:47:06 PM |
So did Bunka complete the heist today? All | Tech99989 | investorshub | 05/10/2023 12:36:19 AM |
Whats even crazier is to remember this stock | PotsandPans420 | investorshub | 05/09/2023 9:47:56 PM |
It took more than 2yr and 5 month | all4weed | investorshub | 05/09/2023 7:00:33 PM |
The guy is so buncking inept. Cant close | Tech99989 | investorshub | 05/09/2023 4:17:12 PM |
If bunka and company truly believe in their | PotsandPans420 | investorshub | 05/09/2023 3:29:25 PM |
True enough didnt expect this to happen. See | codfather | investorshub | 05/09/2023 2:38:37 PM |
Dilution and next Delisting. | willlbone | investorshub | 05/09/2023 1:56:24 PM |
Took a shot at .735. For a | PotsandPans420 | investorshub | 05/09/2023 1:40:19 PM |
You thought that 1.65 purchase was a great | PotsandPans420 | investorshub | 05/09/2023 1:27:30 PM |
great news | Tech99989 | investorshub | 05/09/2023 1:13:22 PM |
Just bought another 1k | codfather | investorshub | 05/09/2023 11:07:36 AM |
.76 pre market | PotsandPans420 | investorshub | 05/09/2023 10:46:19 AM |
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
3.3%Change Percent:
Lexaria Bioscience Corp. Company Name:
LEXX Stock Symbol:
NASDAQ Market:
Lexaria Bioscience Corp. Website:
Lexaria, a global innovator in drug delivery platforms, recently completed dosing of its human pilot study #2, GLP-1-H24-2 The study is to explore the tolerability, side effects, and blood levels of semaglutide, a glucagon-like peptide-1 (“GLP-1”) drug For Lexaria, the results f...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced the receipt of interim results from the first four weeks of dosing in its ongoing diabetes animal study WEIGHT-A24-1. The company noted that the results have already produced several notewort...
(TheNewswire) DehydraTECH appears to work with a second GLP-1 drug – liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC technology DehydraTECH-CBD is showing strong apparent performance relative to GLP-1 D...